These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27349219)

  • 1. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
    Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
    Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.
    Blevins T; Pieber TR; Colón Vega G; Zhang S; Bastyr EJ; Chang AM;
    Diabetes Obes Metab; 2016 Nov; 18(11):1072-1080. PubMed ID: 27234693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3.
    Bergenstal RM; Lunt H; Franek E; Travert F; Mou J; Qu Y; Antalis CJ; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
    Diabetes Obes Metab; 2016 Nov; 18(11):1081-1088. PubMed ID: 27265390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
    Rosenstock J; Marre M; Qu Y; Zhang S; Bastyr EJ; Prince MJ; Chang AM
    Diabetes Obes Metab; 2016 Nov; 18(11):1093-1097. PubMed ID: 27484021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
    Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
    Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naïve Asian patients with type 2 diabetes.
    Hirose T; Cai Z; Yeo KP; Imori M; Ohwaki K; Imaoka T
    J Diabetes Investig; 2018 Jan; 9(1):100-107. PubMed ID: 28371567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.
    Garg S; Dreyer M; Jinnouchi H; Mou J; Qu Y; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():25-33. PubMed ID: 27393697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial.
    Grunberger G; Chen L; Rodriguez A; Tinahones FJ; Jacober SJ; Bue-Valleskey J;
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():34-42. PubMed ID: 27723225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
    Johansen RF; Søndergaard E; Linnebjerg H; Garhyan P; Lam ECQ; Porksen N; Jacober SJ; Nielsen S
    Diabetes Obes Metab; 2018 Feb; 20(2):419-426. PubMed ID: 28817248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
    Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
    Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial.
    Morrow LA; Hompesch M; Jacober SJ; Leng Choi S; Qu Y; Sinha VP
    Diabetes Obes Metab; 2016 Nov; 18(11):1065-1071. PubMed ID: 27169522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
    Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
    Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
    Buse JB; Rodbard HW; Trescoli Serrano C; Luo J; Ivanyi T; Bue-Valleskey J; Hartman ML; Carey MA; Chang AM;
    Diabetes Care; 2016 Jan; 39(1):92-100. PubMed ID: 26577417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.
    Garg S; Selam JL; Bhargava A; Schloot N; Luo J; Zhang Q; Jacobson JG; Hoogwerf BJ
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():43-49. PubMed ID: 27393722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
    Cusi K; Sanyal AJ; Zhang S; Hoogwerf BJ; Chang AM; Jacober SJ; Bue-Valleskey JM; Higdon AN; Bastyr EJ; Haupt A; Hartman ML
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():50-58. PubMed ID: 27723227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
    Ginsberg H; Cariou B; Orchard T; Chen L; Luo J; Bastyr EJ; Bue-Valleskey J; Chang AM; Ivanyi T; Jacober SJ; Hoogwerf BJ
    Diabetes Obes Metab; 2016 Nov; 18(11):1089-1092. PubMed ID: 27486125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.
    Jacober SJ; Prince MJ; Beals JM; Hartman ML; Qu Y; Linnebjerg H; Garhyan P; Haupt A
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():3-16. PubMed ID: 27723228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
    Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
    Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
    Porksen NK; Linnebjerg H; Lam ECQ; Garhyan P; Pachori A; Pratley RE; Smith SR
    Diabetes Obes Metab; 2018 May; 20(5):1193-1201. PubMed ID: 29316143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
    Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
    Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.